• Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub

News

You are here: Home / News

Family Science Education Day

3 April 2025 by Lizzie Cox

Family Science Education Day On Saturday 22nd March, we welcomed some of our amazing families to our Family Science Education Day at the Think Tank …

Family Science Education DayRead More

Wave Life Science Announce Positive Data from FORWARD-53 Clinical Trial

26 March 2025 by John Marrin

Wave Life Sciences announced today positive data following 48 weeks of dosing in the FORWARD-53 clinical trial evaluating the investigational molecule …

Wave Life Science Announce Positive Data from FORWARD-53 Clinical TrialRead More

Dyne Therapeutics Announce New Long Terms Clinical Data from DELIVER Trial of DYNE 251

26 March 2025 by John Marrin

Dyne Therapeutics recently announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating sustained …

Dyne Therapeutics Announce New Long Terms Clinical Data from DELIVER Trial of DYNE 251Read More

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201

24 March 2025 by Mehreen Arif

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of …

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201Read More

Capricor Therapeutics Reports Positive Long-Term Results for Deramiocel in Treating Duchenne Muscular Dystrophy

20 March 2025 by John Marrin

This week Capricor Therapeutics announced positive long-term data from its' ongoing HOPE-2 open-label extension (OLE) clinical trial, highlighting the …

Capricor Therapeutics Reports Positive Long-Term Results for Deramiocel in Treating Duchenne Muscular DystrophyRead More

Action Duchenne’s Statement Regarding Sarepta’s Sad Announcement

19 March 2025 by John Marrin

We are deeply saddened to learn of the passing of a young man who received ELEVIDYS gene therapy for Duchenne muscular dystrophy. Our hearts go out to …

Action Duchenne’s Statement Regarding Sarepta’s Sad AnnouncementRead More

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

12 March 2025 by John Marrin

PepGen's has released an update regarding the CONNECT clinical trials for PGN-EDO51 in Duchenne muscular dystrophy (DMD). PepGen has announced a …

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMDRead More

Roche Shares Top-line Results from Year Two of the EMBARK Phase 3 Clinical Trial.

12 March 2025 by John Marrin

Roche have provided an update on the latest top-line results from the second year of their EMBARK Phase 3 clinical trial (NCT05096221) investigating …

Roche Shares Top-line Results from Year Two of the EMBARK Phase 3 Clinical Trial.Read More

Calling all Siblings and Caregivers of Individuals with Duchenne

5 March 2025 by John Marrin

Help researchers and mental health professionals at the University of Newcastle better understand how Duchenne muscular dystrophy (DMD) impacts …

Calling all Siblings and Caregivers of Individuals with DuchenneRead More

Vamorolone for Duchenne Muscular Dystrophy: A Summary of Evidence So Far

5 March 2025 by John Marrin

DMD Care UK will host a webinar to summarise the evidence for vamorolone as a treatment for Duchenne muscular dystrophy (DMD), and provide an …

Vamorolone for Duchenne Muscular Dystrophy: A Summary of Evidence So FarRead More

Open Letter from the Chair and CEO of Action Duchenne for Rare Disease Day 2025

28 February 2025 by Lizzie Cox

Dear Friends, Supporters, and Advocates, On Rare Disease Day 2025, we stand together to raise awareness, celebrate our community, and drive …

Open Letter from the Chair and CEO of Action Duchenne for Rare Disease Day 2025Read More

Solid Biosciences Shares 90 Day Update From SGT-003 Gene Therapy Trial

26 February 2025 by John Marrin

We're excited to share news that Solid Biosciences has released initial data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, assessing the safety …

Solid Biosciences Shares 90 Day Update From SGT-003 Gene Therapy TrialRead More

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Interim pages omitted …
  • Page 49
  • Go to Next Page »

Footer

Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA

0300 102 1762
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

Site Footer

Fundraising Regulator badge with validation link

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852